颈深淋巴管/结—静脉吻合术(LVA)

Search documents
最高收费21万元!阿尔茨海默病手术被叫停背后:全国已做上千例 监管真空下医院借“创新治疗”之名收费
Mei Ri Jing Ji Xin Wen· 2025-07-10 14:52
在医疗界人士看来,这一喊停并不突然。《每日经济新闻》记者从国内某知名三甲医院神经内科主任医师处了解到,早在国家卫健委通知正式出台前,该主 任医师所在医疗机构所在地的监管部门就已叫停开展该手术,理由是缺乏长期、具有统计学意义的安全性、有效性数据。 接到通知后,这位医师所在的医疗机构就立即叫停了原本正在筹备中的LVA手术。但在卫健委喊停之前,该手术仍然在大量医疗机构中正常开展。 7月8日,国家卫健委网站发布了一则通知,禁止将"颈深淋巴管/结—静脉吻合术(LVA)"应用于阿尔茨海默病的治疗。 公开资料显示,LVA手术并非一种全新术式。作为一种经典的显微外科手术,该手术的研发可追溯到20世纪后半叶,最初主要用于治疗淋巴水肿等淋巴系统 疾病。直到杭州求是医院院长谢庆平将其用于治疗阿尔茨海默病,才逐步在大范围医疗机构中推广实施。 而LVA手术的迅速推广和普及,一方面与中重度阿尔茨海默病缺乏有效治疗手段有关,另一方面,则是医疗机构的盈利需求。但前述主任医师强调,在未经 严格临床验证的前提下,该类手术不能作为常规收费治疗项目存在。换言之,对患者收费几万元到几十万元不等的LVA手术,此前曾长期在政策监管的空白 地带运行。 | ...
国家卫健委叫停一项阿尔茨海默病治疗手术
Xin Jing Bao· 2025-07-10 04:27
Core Viewpoint - The National Health Commission of China has suspended the use of "Cervical Deep Lymphatic-Venous Anastomosis (LVA)" for Alzheimer's disease treatment due to concerns over its safety, efficacy, and lack of high-quality evidence supporting its clinical application [1][9][10] Group 1: Treatment Overview - Alzheimer's disease is a progressive neurodegenerative condition characterized by cognitive impairment and emotional disturbances, leading to significant declines in daily functioning [2] - Traditional treatments primarily involve medication, but drug development for Alzheimer's has been slow, with only a few new drugs approved in the last two decades [2][3] - LVA surgery aims to connect lymphatic vessels to nearby veins to facilitate the drainage of harmful proteins from the brain, potentially improving cognitive function [3][8] Group 2: Clinical Application and Controversy - The LVA procedure has been performed in over 130 hospitals across 28 provinces in China, with more than 200 Alzheimer's patients treated at one hospital alone [3][4] - Despite its growing popularity, the LVA treatment remains controversial and is considered to be in the early exploratory stage of clinical research [4][9] - Patient feedback on the effectiveness of the LVA surgery is polarized, with some reporting improvements while others see no significant benefits [5][6][7] Group 3: Regulatory Response - The National Health Commission's decision to halt the procedure reflects a commitment to patient safety and the need for rigorous evidence before clinical application [1][10] - The Commission has mandated local health authorities to investigate the use of LVA and ensure that medical institutions cease its application until further evidence is available [9][10] - Future clinical research on LVA will be guided by the availability of sufficient preclinical evidence and ethical review [9][10]